Antiviral Drugs - Bangladesh

Bangladesh

The Antiviral Drugs market in Bangladesh is expected to witness a significant rise in revenue, projected to reach US$30.65m in 2024.
This is further expected to grow at an annual rate of 1.54%, resulting in a market volume of US$32.58m by 2028.
When compared globally, United States is anticipated to generate the highest revenue in the Antiviral Drugs market, with an estimated value of US$32,110.00m in 2024.
Bangladesh has seen an increase in demand for antiviral drugs due to the rising prevalence of viral diseases.

Key regions: France, Brazil, South Korea, India, China

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Bangladesh has been steadily growing over the past few years.

Customer preferences: Bangladesh has a high prevalence of infectious diseases, including viral infections such as hepatitis B and C, dengue fever, and influenza. As a result, there is a high demand for antiviral drugs in the country. Customers in Bangladesh tend to prefer affordable drugs that are easily accessible.

Trends in the market: The Antiviral Drugs market in Bangladesh has been experiencing a shift towards generic drugs. This is due to the fact that generic drugs are more affordable than branded drugs. In addition, the government of Bangladesh has been promoting the use of generic drugs in the country. This has led to an increase in the production and availability of generic antiviral drugs in the market.

Local special circumstances: The government of Bangladesh has implemented policies to increase the availability of antiviral drugs in the country. For example, the government has established a program to provide free treatment for hepatitis B and C patients. This has led to an increase in demand for antiviral drugs in the country.

Underlying macroeconomic factors: The healthcare sector in Bangladesh has been growing in recent years. This is due to the increasing population and the rising income levels in the country. As a result, there is a growing demand for healthcare services, including antiviral drugs. In addition, the government of Bangladesh has been investing in the healthcare sector, which has led to an increase in the availability of healthcare services and drugs in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.